Active, not recruiting
Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer
NCT04032418
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States